GSK plc balance sheet

At the end of fiscal 2025, GSK plc had total assets of $82.19bn, total liabilities of $60.73bn and shareholders' equity of $22.02bn. It held $4.57bn in cash against $23.83bn of debt: net debt of $19.26bn.

Balance sheet

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

GSK plc: balance sheet, annual
Fiscal year	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash and equivalents	8.6	6.0	5.2	4.9	6.2	8.6	5.8	4.5	3.7	4.8	4.6
Receivables	—	7.4	8.1	8.2	9.6	9.5	10.6	8.5	9.4	8.6	10.0
Inventory	—	6.3	7.5	7.0	7.9	8.2	7.8	6.2	7.0	7.1	8.0
Total current assets	—	20.6	21.5	21.6	25.9	27.7	25.2	25.1	23.8	21.3	23.5
Goodwill	7.6	7.4	7.8	7.4	14.0	14.5	14.2	8.5	8.7	8.7	9.4
Total assets	—	72.9	76.3	74.1	105.7	109.9	106.8	72.6	75.2	74.5	82.2
Total current liabilities	—	23.4	35.9	28.7	31.9	30.3	32.0	27.5	26.8	27.2	28.8
Short-term debt	—	5.1	3.8	7.4	9.2	5.1	4.9	4.8	3.6	2.9	4.1
Long-term debt	—	18.1	19.3	25.9	31.3	32.0	27.8	20.6	19.4	18.3	19.8
Total debt	15.8	23.2	23.1	33.3	40.5	37.1	32.6	25.3	23.0	21.3	23.8
Total liabilities	—	66.8	71.6	69.4	81.4	81.5	78.0	60.4	58.9	58.1	60.7
Shareholders' equity	13.1	1.4	4.7	4.8	15.1	19.9	20.3	12.8	17.0	17.1	22.0
Non-controlling interests and other (assets − liabilities − equity)	—	4.7	—	—	9.2	8.5	8.5	—	—	—	—
Net debt (negative = net cash)	7.2	17.1	17.9	28.3	34.2	28.5	26.9	20.8	19.2	16.4	19.3

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: GSK vs NVO BMY vs GSK AZN vs GSK

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from GSK plc's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to GSK plc.